Is Vir Biotechnology Stock a Buy?
Early in the coronavirus pandemic, Vir Biotechnology's (NASDAQ: VIR) stock rose -- literally and figuratively -- as it joined the list of biotechs looking for vaccines and therapies for the disease. Vir's shares are down by 47% this year alone. This could be a buying opportunity for long-term investors, but only if Vir has enough growth fuel left in the tank.